Clinical Trials Logo

Other clinical trials

View clinical trials related to Other.

Filter by:

NCT ID: NCT04859946 Active, not recruiting - Clinical trials for Hematologic and Lymphocytic Disorder

Itacitinib for the Prevention of Graft Versus Host Disease

Start date: January 11, 2022
Phase: Phase 1
Study type: Interventional

This phase II trial studies if itacitinib plus standard of care treatment may help prevent graft-versus-host-disease (GVHD) in patients who have received an allogeneic (donor) stem cell transplant. An allogeneic transplant uses blood-making cells from a family member or unrelated donor to remove and replace a patient's abnormal blood cells. Sometimes the transplanted cells from a donor can attack the body's normal cells (called graft-versus-host disease). Giving itacitinib with standard of care treatment after the transplant may stop this from happening.

NCT ID: NCT04854499 Active, not recruiting - Clinical trials for Head and Neck Squamous Cell Carcinoma

Study of Magrolimab Combination Therapy in Patients With Head and Neck Squamous Cell Carcinoma

ELEVATE HNSCC
Start date: September 7, 2021
Phase: Phase 2
Study type: Interventional

The goals of this clinical study are to learn about the safety, tolerability, dosing and effectiveness of the study drug, magrolimab in combination with other anticancer therapies in patients with head and neck squamous cell carcinoma (HNSCC).

NCT ID: NCT04853225 Active, not recruiting - Clinical trials for Pulmonary Disease, Chronic Obstructive

Investigation of Chronic Obstructive Pulmonary Disease (COPD) Phenotypes and Endotypes in China

Start date: April 22, 2020
Phase:
Study type: Observational

This is a non-drug interventional cohort study, which aims to investigate the clinical, radiological and biological factors associated with disease progression in COPD in China. Participants will be recruited from multiple hospitals across Guangdong province categorized as Type A hospitals (those at prefecture-level and above) and Type B hospitals (those below prefecture-level).

NCT ID: NCT04852965 Active, not recruiting - Clinical trials for Anthracycline Induced Cardiotoxicity

Late Anthracycline Induced Cardiotoxicity- Childhood Cancer Survivors

Start date: October 20, 2021
Phase:
Study type: Observational

Anthracyclines treat up to 60% of childhood malignancies with remarkable improvements survival rates. Unfortunately anthracyclines are associated with an increased cardiomyopathy risk. One study showed an almost six-fold greater risk of developing cardiomyopathy compared to sibling controls. A retrospective pilot study showed evidence of subclinical dysfunction (including impaired global longitudinal strain) in 42/52 childhood cancer survivors. There is limited research in this area, therefore current guidelines are based on expert opinion alone and lack consensus. Current methods of detection diagnose cardiomyopathy at an irreversible stage i.e. when the compensatory mechanisms are exhausted and the left ventricular ejection fraction impaired. Small trials have shown that early treatment with standard heart failure therapy may reverse damage, further validation is however required in this cohort. Newer techniques such as tissue doppler and strain rate imaging have shown promise for early prediction of cardiomyopathy in adult studies. Biomarkers such as troponin and NT-proBNP have also shown a correlation with cardiomyopathy. This study (n=208) aims to use echocardiography, strain imaging, holter monitoring and MRI for early detection of cardiomyopathy. Biomarkers, both currently used (for example, troponin and NTproBNP,) and more novel (for example, IL6, MPO, and sST2) will be assessed to see if early cardiomyopathy can be predicted. This study will explore biomarker discovery by analysing an age/gender matched subgroup for the top differentially expressed microRNA and protein biomarkers. Selected biomarkers will then be validated in a larger cohort.

NCT ID: NCT04851964 Active, not recruiting - Clinical trials for Chronic Rhinosinusitis With Nasal Polyps

Efficacy and Safety of Tezepelumab in Participants With Severe Chronic Rhinosinusitis With Nasal Polyposis

WAYPOINT
Start date: April 22, 2021
Phase: Phase 3
Study type: Interventional

A Multicentre, Randomised, Double-Blind, Parallel-Group, Placebo-Controlled Phase 3 Efficacy and Safety Study of Tezepelumab in Participants with Severe Chronic Rhinosinusitis with Nasal Polyposis

NCT ID: NCT04851704 Active, not recruiting - Clinical trials for Parent and Child Emotional Intelligence and Child Self-regulation

Child Self-regulation: A Pilot Study on the Impact of Tuning in to Kids Parent Intervention

N-TIK Pilot
Start date: January 1, 2016
Phase: N/A
Study type: Interventional

The current pilot project will a) adapt an evidence-based psychosocial intervention program and conduct a randomized controlled trial with a group of Norwegian parents of preschool children, b) evaluate the intervention'simpact on child mental health and c) investigate the cognitive and physiological underpinnings of this effect.This pilot study will recruit 40 Norwegian parents of preschool children prior to the transition to starting school. Baseline measures will include parent emotion coaching and parent functioning, child emotion regulation, social and behavioral functioning, child behavioral and physiological indices of cognitive capacity and attention functioning, and school adjustment. Following completion of baseline assessment, parents will be randomized into Intervention or Wait-list conditions. Intervention parents will attend a 6-session group parenting program where they will learn to emotion coach their children and regulate their own emotions. Post-program, Intervention parents will complete program evaluation to determine program feasibility and acceptability. At 6-month follow-up baseline assessments will be repeated for Intervention and Wait-list participants with primary school teachers reporting on children's adjustment to school. Wait-list parents will then be offered the N-TIK program.

NCT ID: NCT04850287 Active, not recruiting - Clinical trials for Health Knowledge, Attitudes, Practice

Improving Health Awareness Using Social Network Interventions

SNI
Start date: February 10, 2021
Phase: N/A
Study type: Interventional

The overarching hypothesis of our study is that social network interventions using artificial intelligence and social media can be used to increase population awareness about health issues. The overarching objective is to improve population awareness on multiple relevant health issues using social network interventions (SNI) and estimate the effect by conducting randomized control trials. Increase population awareness about organ donation in California, especially among minorities

NCT ID: NCT04849416 Active, not recruiting - Clinical trials for Lymphoma, Non-Hodgkin

A Study of LOXO-305 in Chinese Participants With Blood Cancer (Including Lymphoma and Chronic Leukemia)

Start date: May 14, 2021
Phase: Phase 2
Study type: Interventional

A study of the safety, side effects, and effectiveness of LOXO-305 in Chinese adults with lymphoma or chronic leukemia who have already had standard of care treatment. Participation could last up to four years.

NCT ID: NCT04848753 Active, not recruiting - Clinical trials for Resectable Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma

Perioperative Toripalimab (JS001) Combined With Neoadjuvant Chemotherapy in Patients With Resectable Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma

Start date: June 23, 2021
Phase: Phase 3
Study type: Interventional

This is a randomized, placebo-controlled, multi-center, double-blinded, Phase III study to determine the efficacy and safety of patients with locally advanced squamous cell carcinoma of the thoracic esophagus treated with perioperative immunotherapy combined with neoadjuvant chemotherapy versus placebo combined with neoadjuvant chemotherapy.

NCT ID: NCT04847960 Active, not recruiting - Clinical trials for Healthy Subjects With Fixed Orthodontics

The Effect of Probiotic Lactobacillus Reuteri Prodentis Consumption on Gingival Crevicular Fluid Inflammatory Response and Metagenomic Profiles of Oral Microbiome in Orthodontic Patients.

Start date: March 22, 2021
Phase: N/A
Study type: Interventional

In this study, researchers will test the effectiveness of probiotic consumption against oral pathogenic bacteria and reduce the occurrence of gingival inflammation in subjects using orthodontic fixed appliances (braces). Lactobacillus reuteri is one of the probiotic bacteria that has been identified for its health benefits. L. reuteri produces antimicrobial substances, reuterin and reutericyclin which are active against wide range of pathogenic organisms. Previously, investigator performed a pilot study on the beneficial health effect of probiotic L. reuteri containing lozenges on a few orthodontic patients and it was proven that taking this probiotic for two weeks could significantly reduce the number of pathogenic bacteria in the patients' saliva. In vitro study showed that L. reuteri has the ability to modulate the inflammatory response such as TNF alpha and interleukins. However, The ability of L. reuteri in modulating the inflammatory response viz. Interleukin 1-beta, Interleukin 6, interleukin 8, interleukin 10, TNF alpha, MMP-9 and RANKL and effect on oral metagenomic microbiome profile in patients undergoing orthodontic treatment has not been previously investigated. Objective: 1. To evaluate the effect of consumption of L. reuteri Prodentis probiotic lozenges on the inflammatory response (inflammation) of gingival fluid. 2. To evaluate the effect of consumption of the probiotic lozenges of L. reuteri Prodentis against oral pathogens in dental plaque and saliva. Research Benefits: This study was conducted to observe the effectiveness of L. reuteri (ProDentis) probiotic against oral pathogenic bacteria on patients using orthodontic fixed appliance, to reduce gum inflammation and improve oral health.